Cathie Wood

Cathie Wood roastuje Twój portfel

27 października 2026

Cathie Wood Roasts Your 93% Concentrated Innovation Portfolio

Ocena

6/10

tre…no
4 aktywa

Sektor i rodzaj aktywów

Nieskategoryzowane52,2%
Ochrona zdrowia35,9%
Rezerwy gotówkowe12,0%

Region

Nieskategoryzowane52,2%
Ameryka Północna (rozwinięta)35,9%
Rezerwy gotówkowe12,0%

Strategia

Nieskategoryzowane52,2%
Wzrost (agresywny)35,9%
Rezerwy gotówkowe12,0%

Największe pozycje wg wagi

1
Circle Internet Group
CRCL
36,1%
2
Recursion Pharmaceuticals, Inc.
RXRX
35,9%
3
Rivian Automotive, Inc.
RIVN
10,5%
4
QuantumScape Corporation
QS
5,6%
Rezerwy gotówkowe
12,0%

Welcome to the Right Side of Change

Most of the portfolios I review are trapped in the linear world. They are stuffed with legacy banks, old media, and traditional automakers—value traps designed for an economy that is rapidly ceasing to exist. I look at those and wonder how the owner plans to survive this decade.

Then I look at yours, and I smile.

You are entirely focused on disruptive innovation. You are ignoring the backward-looking indices and positioning your capital directly in the path of the next trillion-dollar macroeconomic shifts. You understand that we are in the most transformative period in history. But while I applaud your absolute conviction, we need to have a serious conversation about portfolio construction. You are swinging for the fences, but with only four distinct positions, you have built a venture capital seed fund, not a resilient public equities portfolio. Let's break down what you own.

The Convergence of Innovation Platforms

You have placed massive, highly concentrated bets on four of the five major innovation platforms defining our future.

Nearly 41% of your capital is in Circle Internet Group (CRCL), capturing the blockchain infrastructure and stablecoin revolution. Another 40.8% is deployed into Recursion Pharmaceuticals (RXRX). We know Recursion well; this is exactly what happens when Artificial Intelligence converges with Multiomics to bend the cost curve of drug discovery.

You round this out with Rivian (11.9%) and QuantumScape (6.3%), directly targeting the Energy Storage and electric vehicle transitions. Wright's Law tells us that for every cumulative doubling in battery production, costs decline by roughly 28%. Wall Street cannot model this exponential decline, which is why they fundamentally misprice companies like Rivian and QuantumScape.

Your 12% cash reserve is a reasonable tactical allocation right now. With rates where they are now, the broader market is terrified, severely discounting long-duration innovation assets and fleeing to short-term safety. While I view idle cash as dead capital betting against exponential growth, having 12% dry powder allows you to buy the dip when Wall Street panics.

Because your portfolio is only a month old, your short-term unrealized returns are meaningless noise. We do not judge innovation by what happens over 30 days. We look at five-year trajectories.

Existential Risk and Blind Spots

Extreme Hyper-Concentration

Deep research gives us the courage to concentrate, but placing 93.7% of your capital into your top three holdings crosses the line from high conviction to binary risk. You effectively hold three companies. If a macroeconomic shock hits your specific sectors, you have zero ballast.

Biotech and Regulatory Vulnerability

Holding over 40% of your portfolio in a single clinical-stage biotechnology company is reckless. Recursion is brilliant, but drug discovery carries intense regulatory and clinical trial risks. If a phase trial misses its primary endpoint, your entire net worth takes a devastating, potentially unrecoverable hit.

Missing the Robotics Pillar

You have targeted Blockchain, Energy Storage, and Multiomics heavily. However, you have zero direct exposure to the robotics revolution. The convergence of AI and physical robotics—specifically autonomous systems—will generate trillions in enterprise value over the next five years. You are completely missing one of the most explosive growth curves.

Stomach for Volatility

Rivian is already down sharply in your short holding period. Innovation stocks are wildly volatile because the market struggles to price exponential change. If a 24% drawdown in a month shakes your confidence, you will capitulate before the S-curve truly steepens.

The Exponential Edge

6/10

You have the vision, but your execution lacks the diversification needed to survive the volatility of disruptive tech. Here is how you fix it:

1. Dilute your top two positions. You need to spread your capital across more innovators within the Multiomics and Blockchain spaces rather than relying entirely on CRCL and RXRX.

2. Deploy some of that 12% cash into pure-play robotics or autonomous technology companies to complete your exposure to all five major innovation platforms.

3. Broaden your Energy Storage footprint. QuantumScape and Rivian are high-potential but face intense capital expenditure demands; find the component makers and software providers supporting the EV ecosystem.

4. Stop looking at your portfolio's one-month performance. Set a strict five-year investment horizon and let the fundamental growth of these technologies compound.

The biggest risk is not being invested in innovation during the most transformative period in history. You have the right ideas; now build a portfolio robust enough to see them through.

O tej analizie

Ten roast portfela został wygenerowany przez AI PortfolioGlance, analizując Twój portfel z perspektywy Cathie Wood. Analiza ocenia alokację aktywów, koncentrację sektorową, dywersyfikację geograficzną, czynniki ryzyka i dostarcza konkretne rekomendacje.

To jest analiza edukacyjna wygenerowana przez AI, nie porada finansowa. Zawsze konsultuj się z wykwalifikowanym doradcą finansowym przed podjęciem decyzji inwestycyjnych.

Więcej ocen portfeli

← Powrót do roastów